Highest-materiality recent filing
NHI receives early HSR termination, anticipates July 1 closing of property sale to NHC subsidiary
HSR waiting period terminated early on May 26, 2026, clearing antitrust hurdle.
NHI stockholders elect all 7 director nominees and ratify BDO as auditor at 2026 annual meeting
Approximately 87.46% of outstanding shares were present, constituting a quorum.
NHI Q1 EPS +11% to $0.82 but cuts FY2026 FFO guidance to $4.74-$4.79
Net income per diluted share $0.82 (+10.8% YoY); NAREIT FFO $1.23 (+7.9%).
NHI provides Q1 2026 supplemental; key details unavailable in filing text
Company furnished Q1 2026 supplemental information dated May 4, 2026.
NHI issues investor update with link to presentation; no financial details disclosed.
Press release on May 4, 2026, announces an investor update posted on company website.
NHI CFO John Spaid to retire July 1, 2026; Todd Siefert named successor
John Spaid to retire as EVP/CFO/Treasurer effective July 1, 2026; no disagreement with company.
NHI sells 35 SNF/IL properties to NHC/OP for $560M; strengthens balance sheet
Purchase price $560M; 32 skilled nursing + 3 independent living facilities in 7 states.
NHI signs $560M sale of 35 SNF/IL facilities to NHC; reduces leverage, pivots to private-pay
Purchase price of $560M for 32 skilled nursing + 3 independent living facilities currently leased to NHC.
NHI files $500M at-the-market equity distribution agreement with forward sale options
Equity Distribution Agreement allows sale of up to $500M of common stock through multiple agents.
NHI Q4 Normalized FFO $1.22/share, 2026 guidance $4.94-$4.99
Q4 GAAP EPS $0.80 (vs $0.95 prior yr); NAREIT FFO $1.22; Normalized FFO $1.22 (vs $1.12).
NHI files Q4 2025 supplemental; full financials not in provided exhibit text
Supplemental Information for quarter ended Dec 31, 2025, dated Feb 26, 2026, furnished.
NHI releases investor update presentation with no new financial figures
Filed under Item 7.01; announcement of investor presentation posted on company website.
Appointed Lilly H. Donohue, President & CEO of Everstory Partners, to the board effective February 17, 2026.
National Health Investors enters new CIC severance agreements with CEO, CFO & 3 other NEOs
D. Eric Mendelsohn (CEO): 3.0x multiplier of avg salary+bonus; non-compete for 12 months post-termination if severance paid.
NHI Q3 Normalized FFO $1.32/share, up 28% YoY; raises full-year guidance third time
Net income $0.69/diluted share vs $0.65 YoY; NAREIT FFO $1.09 vs $1.03.
NHI furnishes Q3 2025 supplemental; no specific financial figures disclosed in filing text
Supplemental information for quarter ended September 30, 2025, dated November 6, 2025, furnished as Exhibit 99.1.
NHI issues investor update; no material new facts disclosed
Company filed an investor presentation and press release on November 6, 2025.
Robert G. Adams will not stand for reelection at the 2026 annual meeting; term ends at that meeting.
NHI closes $350M offering of 5.350% Senior Notes due 2033
$350M aggregate principal of 5.350% Senior Notes due Feb 1, 2033 issued at 98.903% of par.
NHI gives default notice to NHC affiliate over non-monetary lease violations covering 35 properties
Default notice sent Sept 8, 2025 for non-compliance with Master Lease on 32 skilled nursing and 3 independent living facilities.
NHI Q2 Normalized FFO $1.22 beats, raises FY guidance, increases dividend
Q2 Normalized FFO per share $1.22 vs $1.18; NAREIT FFO $1.19 vs $1.18; net income $0.79 vs $0.81.
NHI posts Q2 2025 supplemental; no specific results in provided excerpt
Supplemental information for Q2 2025 posted on company website (www.nhireit.com).
NHI issues investor presentation with no new financial data
Company furnished an investor presentation on August 6, 2025, via press release and website.
NHI updates investment pipeline to $331.4M with $126.7M in signed LOIs
Investment pipeline totals ~$331.4M as of June 2, 2025 investor presentation.
NHI shareholders elect four director nominees, approve board declassification
Directors elected: Robert G. Adams, Robert W. Chapin Jr., James R. Jobe, Candice W. Todd; each to serve until 2026 annual meeting.
NHI Q1 EPS $0.74, NAREIT FFO $1.14; raises 2025 guidance mid-point
Net income per diluted share $0.74 vs $0.71 YoY; NAREIT FFO $1.14 vs $1.10; Normalized FFO $1.15 vs $1.12.
National Health Investors releases Q1 2025 supplemental data; no specific numbers in filing excerpt
Supplemental Information for Q1 2025 furnished as Exhibit 99.1 under Item 7.01.
NHI issues investor update but provides no specific financial or operational details
No financial data or strategic announcements included in the filing.
NHI appoints Robert W. Chapin, Jr. to Board, special committee for NHC lease
Robert W. Chapin, Jr. joins NHI Board effective March 27, 2025; will stand for election at 2025 annual meeting.
NHI Q4 net income $0.95/diluted share; introduces 2025 FFO guidance $4.59-$4.66
Q4 2024 NAREIT FFO per diluted share $1.24 (up from $1.09 YoY); Normalized FFO $1.12 vs $1.09.
NHI furnishes Q4 2024 supplemental information; no specific results disclosed in filing
Supplemental Information for quarter ended December 31, 2024 furnished under Item 7.01.
NHI posts investor update on website with no specific financial details
Furnished investor presentation dated February 25, 2025 via press release and website (www.nhireit.com).
NHI director Robert Webb resigns after 34 years; board to shrink to seven
Robert Webb resigned effective February 7, 2025, ending 34 years of board service since NHI's 1991 inception.
Appointments effective January 7, 2025; Todd had been appointed to the Board effective January 1, 2025.
NHI announces board changes, declassification proposal, and governance enhancements
Robert A. McCabe Jr. appointed Chair of Board; Candice W. Todd appointed to board and as Audit Committee Chair.
NHI appoints Candice Todd to Board of Directors effective Jan 1, 2025
Candice Todd appointed to fill seat vacated by retiring director W. Andrew Adams, effective Jan 1, 2025.
NHI Q3 normalized FFO $1.03; cuts 2024 guidance on SLM credit loss and lower revenue
Net income per diluted share Q3 $0.65 (vs $0.68 YoY); Normalized FFO $1.03 (vs $1.08).
NHI furnishes Q3 2024 supplemental information; no data provided in filing text
Company furnished Supplemental Information for Q3 ended Sept 30, 2024, as Exhibit 99.1.
NHI issues investor update; no financial results or guidance provided in filing
Press release directs readers to investor presentation on company website.
NHI Announces Retirement of Chairman W. Andrew Adams
W. Andrew Adams will retire as Chairperson and Board member effective December 31, 2024 after more than 30 years of leadership.
National Health Investors enters amended $700M credit agreement and amends $200M term loan
Entered $700M revolving credit facility maturing Oct 2028, with options to extend by 6 or 12 months upon fee payment.
NHI enters forward sale agreements for 2.76M shares at $68.40; expects net proceeds ~$188.3M
Underwriting agreement dated Aug 14, 2024 for 2,760,000 shares (including 360,000 option exercised) at $68.40 per share.
NHI beats Q2 expectations, raises full-year NAREIT FFO guidance to $4.50-$4.54
Net income per diluted share $0.81 vs $0.92 YoY; NAREIT FFO per share $1.18 vs $1.05 YoY.
NHI furnishes Q2 2024 supplemental information; no financial details disclosed
Supplemental Information for quarter ended June 30, 2024 furnished via Exhibit 99.1.
NHI announces investor update but provides no new financial details
Company issued an investor update via press release on August 6, 2024.
NHI shareholders elect three directors, approve say-on-pay, ratify BDO auditor at annual meeting
D. Eric Mendelsohn (31.1M for), Charlotte Swafford (20.7M for), Robert Webb (19.2M for) elected to board for three-year term.
NHI Q1 Normalized FFO $1.12/share vs $1.11 YoY; full-year guidance raised
Q1 diluted EPS $0.71 (vs $0.79); NAREIT FFO $1.10 (vs $1.16); Normalized FFO $1.12 (vs $1.11).
NHI Q1 2024 supplemental filed; financial metrics not available
Supplemental information covers quarter ended March 31, 2024, dated May 6, 2024.
NHI posts investor update on website; no financial details in filing
Press release directs investors to nhireit.com for the May 6, 2024 investor presentation.
On March 27, 2025, National Health Investors, Inc. (the “Company” or “NHI”) announced that, upon the recommendation of its Nominating and Corporate Governance Committee, it has increased the size of the Board to eight members and has appointed Robert W. Chapin, Jr. to fill the newly created seat on the Board, effective immediately.
On February 7, 2025, Robert T. Webb notified National Health Investors, Inc. (the “Company”) of his decision to resign from his position as a member of the Board of Directors (the “Board”) effective immediately.
Appointed Ms. Todd as a member of the Special Committee related to the National HealthCare Corporation potential lease.
Appointed Ms. Todd as Chairperson of the Audit Committee;
Appointed Ms. Todd as a member of the Nominating and Corporate Governance Committee;
on December 2, 2024, the Company announced that upon the recommendation of its Nominating and Corporate Governance Committee, it has appointed Candice W. Todd to fill the soon to be vacant seat on the Board, effective January 1, 2025.
on November 5, 2024 the Company announced the retirement of Mr. W. Andrew Adams from the Board effective December 31, 2024.
W. Andrew Adams notified National Health Investors, Inc. (the “Company”) of his decision to retire from his position as Chairperson and a member of the Board of Directors (the “Board”) effective December 31, 2024.
Max materiality 0.90 · Median 0.30 · Most common event other_material